is fortunately low, less than 1 % in most studies. Those who have significant pre-existing cardiorespiratory disease, such as those with severe congenital heart disease,4 bronchopulmonary dysplasia, or cystic fibrosis, and those who are immunosuppressed' are at considerably increased risk and mortality in excess of 30% has been reported. CHRONIC 
BRONCHIOLITIS
There are also a few babies,6 again less than 1%, who fail to make the expected recovery and who have persisting respiratory distress with hyperinflation, crepitations with or without wheezing, oxygen dependency, feeding problems, and often failure to thrive lasting for many weeks or even months. Most of these babies have bronchiolitis due to specific adenovirus strains, particularly 7 and 21; but probably respiratory syncytial virus itself can produce this picture. At necropsy or lung biopsy the histological appearance is grossly abnormal with areas of hyperinflation and collapse and grossly abnormal small airways-hence the term obliterative bronchiolitis. Although most of these infants do eventually thrive and lose their oxygen dependence, some at least have persisting abnormalities and restriction of exercise tolerance even in later childhood. We do not yet know what the impact of this condition will be on respiratory reserve and decay in lung function in adult life.
ABNORMAL AIRWAY LABILITY
Several studies have shown that a high proportion of babies admitted to hospital with acute bronchiolitis will have subsequent attacks of coughing and wheezing associated with abnormal airway lability. Studies have shown that 75% of such babies will have symptoms ofwheezing over the subsequent two years,7 and that the incidence of wheezing falls to 42% by the age of 5 The third difference has emerged from investigation of the family history of atopy and asthma. No difference was seen in the incidence of wheezing8 or diagnosed asthma in first degree relatives of index patients and controls. In an attempt to evaluate the contribution of genetic factors to the increase in bronchial responsiveness to methacholine that is seen after respiratory syncytial virus infection, Gurwitz et al2 tested the first degree relatives. They found that 33% of first degree relatives of hyperreactive index patients had a positive response to bronchial challenge. Unfortunately they did not test the first degree relatives ofchildren without a positive response to methacholine, nor did they recruit a separate control group. This work therefore needs repeating.
These observations suggest that infection with respiratory-syncytial virus is probably itself responsible for the abnormal airway lability that persists for five to 10 years after the attack. Interestingly, in adults upper respiratory infections due to respiratory syncytial virus may be associated with increased bronchial reactivity for several weeks after the illness.'3 The pathological basis of increased airway lability after bronchiolitis in children is not known.
In the acute attack there is little doubt that the epithelium is damaged, creating a condition in which short term abnormalities of airway lability might be expected, similar to those in adults who have suffered severe influenzal infections.'4 Possibly recurrent infections by other viruses are necessary to perpetuate the abnormal airway lability and, indeed, many of these children will wheeze only at times when they have upper respiratory tract infections and even in infancy may lose their bronchoconstrictor response to mist at times when they are free from infection. Interestingly, one follow up study'5 has shown that babies developing acute bronchiolitis but not having symptoms of sufficient severity to require admission to hospital suffered far fewer subsequent respiratory problems. An alternative explanation, that respiratory syncytial virus bronchiolitis is selecting out those babies likely to develop asthma on the basis of an inherited tendency to abnormal airway lability,'6 is difficult to sustain. The lack of a significant association with personal or family history of atopy militates against this hypothesis.
A further possibility relates to the observation by Mist treatment has been given in the past in the hope that this would help to clear the secretions and debris that block the small airways. There is now good evidence that giving particulate water from either a conventional or an ultrasonic nebuliser to babies with abnormal airway lability will actually induce bronchoconstriction lasting for 10-15 minutes. 9 The humidifying devices used in the past-that is, croupettes-were totally ineffective, raising the water content only to about 20 mg/I, less than half that achieved by drawing air through the naries.
PHYSIOTHERAPY
Physiotherapy is also a popular form of treatment, again given in the hope that it will clear secretions from the airways. The single controlled study,30 carried out on 96 children admitted over two seasons, failed to show any benefit from physiotherapy, and indeed, there is some anecdotal evidence that babies may deteriorate rapidly during vigorous physiotherapy sessions with apnoea requiring intubation and subsequent respiratory support.
ANTIVIRAL AGENTS
There is now an antiviral agent, ribavirin, that is effective against respiratory syncytial virus.3' It is given as an aerosol with a device (SPAG) producing a fine mist with a median particle size of only 13 gm. The output of the nebuliser is fed into a headbox. The extent to which the ribavirin penetrates into the bronchioles in these babies is not known. The small particle size would suggest that at least some will penetrate deep into the lungs. The optimal time for treatment has also not been defined. In one study treatment that was given for only 12 hours produced less satisfactory results than when treatment was given for about 20 out of the 24 hours. 32 Ribavirin given in this manner appears to be free of worrying side effects. When given orally in large doses it produces teratogenic changes in pregnant rodents33 but the amount taken up by medical and nursing staff 4 caring for these babies appears to be negligible. Certainly there is too little in the blood to register even with highly sensitive assays. So far four double blind clinical trials have been published, assessing the effect of nebulised ribavirin and placebo on babies with acute bronchiolitis who had been previously well. 32 3436 In all four studies resolution of symptoms tended to occur more rapidly in babies receiving ribavirin than in controls, and in two studies oxygenation improved significantly with ribavirin treatment.34 6 In only one study, however, was elimination of virus from the respiratory tract accelerated and there was no evidence to suggest that treatment with ribavirin allowed the children to be discharged from hospital earlier. The studies are too small to detect any effect on mortality in these previously well babies. 37 Two studies have been carried out in babies with pre-existing cardiopulmonary disease, a group of children with significantly increased mortality from bronchiolitis. In one study 33 treated patients were compared with 97 admitted during the same epidemic. The authors claimed that the ribavirin was associated with a more rapid resolution of symptoms, but as this was not a formal, controlled study interpretation of the results is difficult.38 In the one controlled trial in this group of patients there again appeared to be benefit from treatment within 24-48 hours, but happily no deaths occurred in either the treated or the control babies. 39 In our current state of knowledge giving ribavirin, despite its cost, to babies who have severe pre-existing cardiorespiratory disease would seem reasonable, in the hope that it may prevent death in at least some. It is much more difficult, however, to justify giving it to babies who have been previously well, unless they become critically ill and require assisted ventilation. Ribavirin can then be introduced into the ventilator circuit, although this is not without its problems as ribavirin tends to build up in the circuit and cause the expiratory valves to stick unless special filters are inserted. If, however, ribavirin treatment during the acute phase can be shown to modify longer term morbidity, this recommendation will obviously have to be reconsidered.3' PROPHYLAXIS As respiratory syncytial virus infections produce so much morbidity, several attempts have been made to produce a vaccine. Theoretically, this should not be a major problem as there are only two subtypes. The killed vaccine produced in the 1960s certainly led to a good IGg response in healthy volunteers but when it was assessed in clinical trials the severity of the subsequent infection in those who had been immunised was increased rather than reduced.'" There are now attempts to produce either a modified live vaccine that could be given either by injection or directly to the respiratory tract or to use genetic engineering to produce surface antigens that could be given with relative safety. As the babies who suffer most from bronchiolitis are those less than 3 months of age, the vaccine might even need to be given to mothers during the third trimester. In support of this is a paper indicating that high maternal respiratory syncytial virus antibody titres have a protective effect in early infancy. 4' Although acute bronchiolitis has so far proved unresponsive to a wide range of treatments, the development of effective vaccines and antiviral agents may dramatically alter this in the near future. If so, we may be able to reduce the incidence of asthma in.early childhood and perhaps even reduce the frequency and severity of respiratory disease throughout life. Meanwhile acute bronchiolitis and its sequelae warrant careful study, as this is a setting in which asthma may well be caused largely by environmental rather than genetic factors.
